Amy Yoder - 01 Jun 2022 Form 4 Insider Report for Arcadia Biosciences, Inc. (RKDA)

Reporting relationship: Director
Issuer ticker: RKDA
Reported as of: 01 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2022, 13:23:45 UTC
Prior SEC filing: 19 May 2022
Next SEC filing: 09 Aug 2022
Source filing: View source filing
Reporting owner signature: Amy J. Yoder, by Attorney-in-Fact, Cesare Suardi

Key filing fact

Amy Yoder filed Form 4 for Arcadia Biosciences, Inc. (RKDA) on 03 Jun 2022.

Key facts

This page summarizes Amy Yoder's Form 4 filing for Arcadia Biosciences, Inc. (RKDA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2022, 13:23.

Change

Previous filing in this sequence was filed on 19 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RKDA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +23,620
Change %: +59%
Price: $0.000000
Shares after: 63,931
Date: 01 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,620
Exercise price: $1.34
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Option will become 100% vested and exercisable on the earlier to occur of (i) June 1, 2023 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.